^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AXL overexpression + KRAS G12C

    i
    Other names: AXL Receptor Tyrosine Kinase, Tyrosine Protein Kinase Receptor UFO, AXL Oncogene, AXL Transforming Sequence Gene, Tyro7, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 558
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    9ms
    AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells. (PubMed, Cancer Lett)
    In xenograft models of AXL-overexpressing KRAS G12C-mutated lung cancer treated with KRAS G12C inhibitors, initial combination therapy with AXL inhibitor markedly delayed tumor regrowth compared with KRAS G12C inhibitor alone or with the combination after acquired resistance to KRAS G12C inhibitor. These results indicated pivotal roles for the YAP-GAS6-AXL axis and its inhibition in the intrinsic resistance to KRAS G12C inhibitor.
    Journal • Tumor cell
    |
    KRAS (KRAS proto-oncogene GTPase) • GAS6 (Growth arrest specific 6)
    |
    KRAS mutation • AXL overexpression • KRAS overexpression • AXL overexpression + KRAS G12C